Thesis

188 Part II Chapter 8 Table 1. Patient characteristics of the denosumab group Patient nr Treatment, reason Treatment dose Interval Scan 1 to Dmab (weeks) Interval Scan 1, scan 2 (weeks) Interval Scan to BTM Scan 1 (weeks) Baseline SBS MFD/ PFD/ MAS Location FD 1 Growth + BTMs progression Dmab (60mg every 3 months) 2.4* 59 4.6 3.41 MFD CF: zygoma / orbita 2 Growth + BTMs progression Dmab (60mg every 6 months) 13.4 90 0.4 5.60 PFD Spine, ribs 3 Pain and BTMs progression Dmab (60mg every 6 months) 2.0 54 0.4 0.26 PFD Mandibula, maxilla, ribs 4 Pain and BTMs progression Dmab (60mg every 3 months) 1.9 64 2.1 16.70 PFD Pelvis, left femur and tibia 5 Pain and BTMs progression Dmab (60mg every 6 months), onwards increased up to 120 mg every 3 months 3.0 61 14.3 2.05 PFD Ribs, thoracic spine, pelvis 6 Pain and BTMs progression Dmab (60mg every 3 months) 1.7 65 2.7 16.68 PFD L4, iliac bone, femur, fibula 7 Pain and BTMs progression Dmab (60mg every 3 months) 1.7 56 3.3 37.70 MAS Skull, spine, pelvis 8 Pain and BTMs progression Dmab (60mg every 3 months) 10.0 78 4.4 25.28 MAS Spine, ribs, pelvis, femur * = denosumab was started before scan 1, otherwise scan 1 was performed before start of denosumab

RkJQdWJsaXNoZXIy MjY0ODMw